Sevinç M, Kirkali Z, Yörükoğlu K, Mungan U, Sade M
Department of Urology, Dokuz Eylül University School of Medicine, Izmir, Turkey.
Eur Urol. 2000 Dec;38(6):728-33. doi: 10.1159/000020370.
The treatment of localized and even advanced renal cell carcinoma (RCC) is radical nephrectomy. However, 30% of these patients progress after radical nephrectomy. Prognostic factors are needed in order to determine the course of disease in patients undergoing radical nephrectomy. The aim of this study is to study the prognostic significance of microvascular invasion (MVI) in patients who had undergone radical nephrectomy for localized RCC.
Between June 1989 and February 1999, pathologic sections of the specimens from 41 patients without metastases, nodal involvement or macroscopic venous involvement were investigated for MVI.
MVI was observed in 17% of the patients. MVI was related to the grade of the tumor and tumor size (p = 0.032, p = 0.017). In sarcomatoid-type RCC, MVI was more common than in other histologic types (p = 0.003). After a median follow-up of 48 months, the progression rate was 29% in patients with MVI and 17% without MVI (p = 0.001). Median progression time was 3 months in those with MVI and 41 months with no MVI (p = 0.01). The survival rate decreased from 85 to 70% in patients with MVI during a median follow-up of 48 months (p = 0.031). In multivariate analysis, MVI was not found to be an independent prognostic factor.
Although MVI is closely related to progression and prognosis, in multivariate analysis it was not found to be an independent prognostic factor in localized RCC. We conclude that MVI should also be evaluated together with tumor grade in predicting the prognosis of patients with localized RCC.
局限性甚至晚期肾细胞癌(RCC)的治疗方法是根治性肾切除术。然而,这些患者中有30%在根治性肾切除术后病情进展。为了确定接受根治性肾切除术患者的疾病进程,需要预后因素。本研究的目的是探讨微血管侵犯(MVI)在接受局限性RCC根治性肾切除术患者中的预后意义。
在1989年6月至1999年2月期间,对41例无转移、无淋巴结受累或无肉眼可见静脉受累患者的标本病理切片进行MVI研究。
17%的患者观察到MVI。MVI与肿瘤分级和肿瘤大小相关(p = 0.032,p = 0.017)。在肉瘤样型RCC中,MVI比其他组织学类型更常见(p = 0.003)。中位随访48个月后,有MVI的患者进展率为29%,无MVI的患者为17%(p = 0.001)。有MVI的患者中位进展时间为3个月,无MVI的患者为41个月(p = 0.01)。在中位随访48个月期间,有MVI的患者生存率从85%降至70%(p = 0.031)。多因素分析中,未发现MVI是独立的预后因素。
虽然MVI与疾病进展和预后密切相关,但在多因素分析中,未发现其是局限性RCC的独立预后因素。我们得出结论,在预测局限性RCC患者的预后时,MVI也应与肿瘤分级一起评估。